For the demanding of novel targeted therapeutics mentioned above, we investigate and demonstrate the substantial inhibition of ERK, AKT-mTOR and STAT3 signaling pathways by HS7 in EGFR-TKI resistant CL1-0 human NSCLC cells (EGFR wild-type). This evidence concerns the gene EGFR and non-small cell lung carcinoma.